In patients with advanced NSCLC with high PD-L1 expression without targetable driver mutations, both first line chemo-immunotherapy and immune check-point monotherapy as first-line treatment for advanced NSCLC result in similar overall survival according recent meta-analyses of randomized trials. This evidence concerns the gene CD274 and non-small cell lung carcinoma.